Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2021-08-06 Interim / Quarterly Rep…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2021
2021-08-06 English
S-8_INDUCEMENTPLAN
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans or inducement plans. It includes details about the securities to be registered, the registration fee, incorporation by reference of prior filings (including the 10-K), and indemnification provisions. It is not an annual report, earnings release, or any other financial report but a registration statement related to equity inducement plan shares. This type of filing is related to capital raising or equity issuance activities under employee plans. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed registration information, not just an announcement or certification, so it is not RPA or RNS. Confidence is high given the clear identification as Form S-8 and the content focused on registration of shares under an inducement plan.
2021-08-06 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a lease amendment extending the lease term and financial obligations related to it. There are no financial statements or comprehensive financial data presented, only a description of the lease amendment and its financial impact. The document is relatively short (3853 characters) and serves as an announcement of a material event rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as lease agreements that create financial obligations.
2021-06-17 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-07 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.